AAVCAGsCD59 for the Treatment of Wet AMD
A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)
Sponsor: Janssen Research & Development, LLC
A PHASE1 clinical study on Wet Age-related Macular Degeneration, this trial is completed. The trial is conducted by Janssen Research & Development, LLC and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .